Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 359-368

  Spiegel, Hans M L ^d   DeFalcon, Elizabeth ^d   Ogg, Graham S ^b   Larsson, Marie ^d   Beadle, Tom J ^d   Tao, Peter ^d   McMichael, Andrew J ^b   Bhardwaj, Nina ^d   O'Callaghan, Chris ^b   Cox, William I ^a   Krasinski, Keith ^d   Pollack, Henry ^d   Borkowsky, William ^d   Nixon, Douglas F ^c  

^a Virogenetics Corporation   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ROCKEFELLER UNIVERSITY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CHILD; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANT; LYMPHOCYTE COUNT; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY TESTS, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; GENE PRODUCTS, NEF; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HIV-1; HLA-B8 ANTIGEN; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; PEPTIDE FRAGMENTS; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD; VIREMIA;

EID: 0001226731     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314867     Document Type: Article

References (46)

1. 1. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999;179:527-37.
2. 2. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamívudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-9.
3. 3. Palella FJJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
4. 4. Autran B, Li TS, Tubiana R, et al. Restoration of CD4 T helper cell functions in advanced patients after combined anti-retroviral therapies. 4th Conf Retro Opportun Infect 1997:164.
5. 5. Autran B, Carcelain G, Li T, et al. Positive effects of combined antiretroviral therapy on CD4' T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
6. + repertoire during antiviral therapy. Nat Med 1998;4:215-21.
7. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40.
8. + T cell responses associated with control of viremia. Science 1997;278: 1447-50.
9. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998;4:953-6.
10. 10. Morris L, Binley JM, Clas BA, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998;188:233-45.
11. 11. Melvin AJ, Mohan KM, Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997;16:968-74.
12. 12. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997;336:1343-9.
13. 13. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B, Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997;11:F107-11.
14. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
15. 15. Kitchen SG, Zack JA. CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus. J Virol 1997;71:6928-34.
16. 16. Rouzioux C, Burgard M, Chaix ML, et al. Human immunodeficiency virus-1 infection in neonates: correlation of plasma and cellular viremia and clinical outcome: French Pediatric Cohort Study Group. Acta Paediatr Suppl 1997;421:17-21.
17. 17. Solder B, Wintergerst U, Notheis G, Eberle J, Gurtler L, Belohradsky BH. Effect of antiretroviral combination therapy zidovudine/didanosine or zidovudine/ lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus. J Pediatr 1997;130:293-9.
18. 18. Valentine ME, Jackson CR, Vavro C, et al. Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immu-nodeficiency virus infected pediatric patients. Pediatr Infect Dis J 1998; 17:18-23.
19. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-10.
20. 20. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune response with the initial control of viremia in primary HIV-1 syndrome. J Virol 1994;68:4650-5.
21. 21. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337:1267-74.
22. 22. Ogg G, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
23. 23. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-72.
24. 24. Rinaldo CR, Beltz LA, Huang XL, Gupta P, Fan Z, Torpey DJ III. Anti HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res Hum Retroviruses 1995;11:481-9.
25. 25. Riviere Y, McChesney MB, Porrot F, et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses 1995;11:903-7.
26. 26. Wagner L, Yang O, Garcia-Zepeda E, et al. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998;391:908-11.
27. + cells: evidence for HLA class 1-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997;71: 3120-8.
28. 28. Altman JD, Moss PAH, Golder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
29. 29. Dalod M, Harzic M, Pellegrin I, et al. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 1998;178:61-9.
30. 30. Nixon D, Douck D, Kuebler P, et al. Molecular tracking of an human immunodeficiency virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy. Immunol Lett 1999;66:219-28.
31. 31. Ogg G, Jin X, Bonhoeffer S, et al. Decay kinetics of HIV-specific cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73: 797-800.
32. 32. Buseyne F, Blanche S, Schmitt D, Griscelli C, Rivière Y. Detection of HIV-specific cell-mediated cytotoxicity in the peripheral blood from infected 7 children. J Immunol 1993;150:3569-81.
33. 33. Luzuriaga K, Holmes D, Hereema A, Wong J, Panicali DL, Sullivan JL. HIV-1 specific cytotoxic T lymphocyte responses in the first year of life. J Immunol 1995;154:433-43
34. 34. Pikora CA, Sullivan JL, Panicali D, Luzuriaga K. Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J Exp Med 1997;185:1153-61.
35. 35. Beatty PR, Krams SM, Esquivel CO, Martinez OM. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation 1998;65:1248-55.
36. 36. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-5.
37. 37. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-79.
38. 38. Jin X, Roberts C, Nixon D, et al. Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte (CTL) responses and their relationship to vertical HIV transmission. J Infect Dis 1998;178:1317-26.
39. 39. Larsson M, Jin X, Ramratnam B, et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of pol-specific CD8 T cells in HIV-1 positive individuals. AIDS 1998;13:767-77.
40. 40. Marsh SG. Nomenclature for factors of the HLA system. Tissue Antigens 1995;45:220-2.
41. 41. Marsh SG. Nomenclature for factors of the HLA system. Tissue Antigens 1996;48:725-6.
42. + T-cells during an acute virus infection. Immunity 1998;8:167-75.
43. 43. Murali-Krishna K, Altman J, Suresh M, et al. Counting antigen-specific CD8 T-cells: a reevaluation of bystander activation during viral infection. Immunity 1998;8:177-87.
44. 44. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997;336:1343-9.
45. 45. Zack JA, Haislip AM, Krogstad P, Chen IS. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992;66: 1717-25.
46. 46. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-7.